Corneal advanced glycation end precincts increase in patients with proliferative diabetic retinopathy

被引:62
作者
Sato, E [1 ]
Mori, F [1 ]
Igarashi, S [1 ]
Abiko, T [1 ]
Takeda, M [1 ]
Ishiko, S [1 ]
Yoshida, A [1 ]
机构
[1] Asahikawa Med Coll, Dept Ophthalmol, Asahikawa, Hokkaido 0788510, Japan
关键词
D O I
10.2337/diacare.24.3.479
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To evaluate corneal advanced glycation end product (AGE) fluorescence in patients with diabetes and in healthy control subjects. RESEARCH DESIGN AND METHODS - Corneal autofluorescence was measured in 26 eyes of 26 patients with type 2 diabetes (mean age 57.0 years; mean disease duration 12.2 years; mean HbA(1c) 7.1%) and 13 eyes of 13 healthy age-matched control subjects (mean age 57.9 years). The patients with type 2 diabetes were divided into the following groups: patients without diabetic retinopathy (DR), patients without proliferative diabetic retinopathy (PDR), and patients with PDR. Corneal autofluorescence was measured by fluorophorometry with the wavelength that is characteristic of AGE fluorescence (excitation and emission 360-370 nm and 430-450 nm, respectively). We defined peak corneal autofluorescence levels as corneal AGE fluorescence values. We compared the corneal AGE fluorescence values in the four groups. RESULTS - In the PDR group (11,9 +/- 3.9 arbitrary units [mean +/- SDI), the corneal AGE fluorescence values were significantly higher compared with the control subjects (6.9 +/- 1.3 arbitrary units), the patients without DR (7.4 +/- 2.1 arbitrary units), and the patients without PDR (6,9 +/- 2.2 arbitrary units) (P < 0.05), CONCLUSIONS - We found that corneal AGEs may increase in patients with diabetes and PDR compared with control subjects, patients without DR, and patients without FDR. In the patients with PDR, increased corneal AGEs may play a role in diabetic keratopathy.
引用
收藏
页码:479 / 482
页数:4
相关论文
共 28 条
[1]   Relationship between autofluorescence and advanced glycation end products in diabetic lenses [J].
Abiko, T ;
Abiko, A ;
Ishiko, S ;
Takeda, M ;
Horiuchi, S ;
Yoshida, A .
EXPERIMENTAL EYE RESEARCH, 1999, 68 (03) :361-366
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[3]   Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content - Vascular endothelial growth factor decreases occludin in retinal endothelial cells [J].
Antonetti, DA ;
Barber, AJ ;
Khin, S ;
Lieth, E ;
Tarbell, JM ;
Gardner, TW .
DIABETES, 1998, 47 (12) :1953-1959
[4]  
BURSELL SE, 1984, INVEST OPHTH VIS SCI, V25, P703
[5]   CORNEAL EPITHELIAL CHANGES IN DIABETIC RATS [J].
FRIEND, J ;
ISHII, Y ;
THOFT, RA .
OPHTHALMIC RESEARCH, 1982, 14 (04) :269-278
[6]   Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nε-(carboxymethyl) lysine independently of glycohaemoglobin concentrations [J].
Hammes, HP ;
Brownlee, M ;
Lin, J ;
Schleicher, E ;
Bretzel, RG .
DIABETOLOGIA, 1999, 42 (05) :603-607
[7]  
HAMMES HP, 1994, DIABETOLOGIA, V37, P32
[8]   Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells [J].
Hirata, C ;
Nakano, K ;
Nakamura, N ;
Kitagawa, Y ;
Shigeta, H ;
Hasegawa, G ;
Ogata, M ;
Ikeda, T ;
Sawa, H ;
Nakamura, K ;
Ienaga, K ;
Obayashi, H ;
Kondo, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (03) :712-715
[9]  
Kaji Y, 2000, INVEST OPHTH VIS SCI, V41, P362
[10]   STRUCTURAL AND FUNCTIONAL-STUDIES OF THE CORNEAL ENDOTHELIUM IN DIABETES-MELLITUS [J].
KEOLEIAN, GM ;
PACH, JM ;
HODGE, DO ;
TROCME, SD ;
BOURNE, WM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1992, 113 (01) :64-70